PubHawk
February 2014 PMID 24184249

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Yoshihiro Matsumoto, Yasuo Mori, Shinji Kageyama, Kazuo Arihara, Toshikazu Sugiyama, Hiromichi Ohmura, Toru Yakushigawa, Hatsumi Sugiyama, Yasushi Shimada, Youichi Nojima, Nobuo Shio

Full text PDF Download social card

Mentions

15
Peak: 2 in Jun 2024
across 4 sources since Sep 2019

Extended reach

31,032
potential audience

Total likes

60

Video views

4,500

Mentions per month

Sep 2019 – Jun 2025

Where it's discussed

  • X / Twitter7 posts
  • Blogs4 articles
  • YouTube2 videos
  • Facebook2 posts

AI synopsis

What people are saying

The discussions show a positive tone, referencing the study as impactful and potentially transformative, with users using words like 'significant' and 'reduces' to emphasize the importance. Some posts question the size and longevity of the effects, reflecting a cautious yet interested stance, which indicates a blend of support and critical evaluation.

AgreementModerate agreement

Most posts support the findings, reflecting general agreement with the study's positive conclusions about spironolactone's benefits.

InterestHigh interest

The high interest score indicates users are highly engaged and curious about the implications of this research for patient care.

EngagementModerate engagement

Posts demonstrate moderate engagement, with some discussing trials, skepticism, and potential clinical impact, rather than surface-level mentions.

ImpactModerate impact

The discussions suggest that the study could influence future research and treatment approaches for hemodialysis patients, though some remain cautious.

Abstract in brief

  • This study investigated whether spironolactone, a medication that blocks aldosterone receptors, can reduce the risk of heart and stroke-related illnesses and deaths in hemodialysis patients and found that it significantly lowered these risks over three years.
  • Patients taking spironolactone experienced fewer cardiovascular events and deaths compared to those who did not, although some side effects like breast pain and hyperkalemia were noted, with a small number having to stop treatment.
  • The results suggest that spironolactone could be an effective way to improve health outcomes for hemodialysis patients, but larger studies are needed to confirm these findings.
Read the full abstract

Top posts

Most liked on X and Bluesky
Ryu
@Ryu04196650Ryu · X

MRAの有効性の報告↓ ●https://t.co/CKzUmu4w4F ●https://t.co/wxKxyusa70 ●https://t.co/4PziqSNOL3 ※SPin-D、MiREnDa trialは有効性を示せず ※ALCHEMIST、ACHIEVEは結果待ち(negative?)

Mar 11, 2024 · 7 likes · 4,936 followers View post →
ちろ剤師
@Toki_nd2525 · X

スピロノラクトンは血液透析患者の心血管疾患および脳血管疾患の罹患率と死亡率を低下させる Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients - PubMed https://t.co/ziX1STb9Uk

Jun 14, 2024 · 2 likes · 5,863 followers View post →
長澤　将（腎臓内科医）
@RealTNagasawa · X

@BKNoil @silentkneecap こちらも参考になると思います。https://t.co/edVlCJzqOr

Sep 9, 2021 · 1 like · 5,368 followers View post →
Ryu
@Ryu04196650Ryu · X

@JACCJournals @NDTsocial @Kidney_Int @CJASN spironolactoneの心血管イベント抑制効果をみた小規模RCT @JACCJournals 3年後の心血管イベントを有意に抑制 Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. https://t.co/CKzUmu4w4F

Jun 20, 2024 · 1 like · 4,936 followers View post →
B. Wagner, M.D.
@Wagner_Nephro · X

Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients cited by Assistant Professor of Medicine Dr. Shan Shan Chen, M.D., University of New Mexico School of Medicine #Nephrology conference https://t.co/C6eyThOR2y

Sep 30, 2019 · 1 like · 3,328 followers View post →
くりにかる3A5＠Ph.D.
@clinical89314 · X

Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients - ScienceDirect https://t.co/ZkYgSSprsK

Jun 28, 2025 · 1,320 followers View post →

All mentions

くりにかる3A5＠Ph.D.
@clinical89314 · X

Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients - ScienceDirect https://t.co/ZkYgSSprsK

Jun 28, 2025 · 1,320 followers View post →
Ryu
@Ryu04196650Ryu · X

@JACCJournals @NDTsocial @Kidney_Int @CJASN spironolactoneの心血管イベント抑制効果をみた小規模RCT @JACCJournals 3年後の心血管イベントを有意に抑制 Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. https://t.co/CKzUmu4w4F

Jun 20, 2024 · 1 like · 4,936 followers View post →
ちろ剤師
@Toki_nd2525 · X

スピロノラクトンは血液透析患者の心血管疾患および脳血管疾患の罹患率と死亡率を低下させる Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients - PubMed https://t.co/ziX1STb9Uk

Jun 14, 2024 · 2 likes · 5,863 followers View post →
Ryu
@Ryu04196650Ryu · X

MRAの有効性の報告↓ ●https://t.co/CKzUmu4w4F ●https://t.co/wxKxyusa70 ●https://t.co/4PziqSNOL3 ※SPin-D、MiREnDa trialは有効性を示せず ※ALCHEMIST、ACHIEVEは結果待ち(negative?)

Mar 11, 2024 · 7 likes · 4,936 followers View post →
J. Brian Byrd
@jbrianbyrd · X

@DGBassani @thebyrdlab In this instance, I’m trying to judge others’ big effect finding The condition is a high mortality one; bigger trials are ongoing. But many current patients will have died when results available. There has been much skepticism about whether effect too big https://t.co/mq1Ue8hew6

Oct 7, 2021 · 782 followers View post →
長澤　将（腎臓内科医）
@RealTNagasawa · X

@BKNoil @silentkneecap こちらも参考になると思います。https://t.co/edVlCJzqOr

Sep 9, 2021 · 1 like · 5,368 followers View post →
B. Wagner, M.D.
@Wagner_Nephro · X

Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients cited by Assistant Professor of Medicine Dr. Shan Shan Chen, M.D., University of New Mexico School of Medicine #Nephrology conference https://t.co/C6eyThOR2y

Sep 30, 2019 · 1 like · 3,328 followers View post →